摘要
目的:观察贝伐珠单抗靶向治疗联合TC化疗方案治疗晚期非小细胞肺癌的疗效。方法:选择我院2017年1月—2020年12月期间收治的晚期非小细胞肺癌患者50例,随机分为对照组与观察组,各25例,对照组采用标准TC化疗方案,观察组应用贝伐珠单抗靶向治疗联合TC化疗方案,观察比较两组临床疗效、血清血管内皮生长因子(VEGF)、血清癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)水平、癌症患者生存质量(EORTC-QLQ-C30)评分及毒副反应情况。结果:观察组临床缓解率与疾病控制率高于对照组(P<0.05);观察组血清VEGF、CEA、CYFRA21-1水平均低于对照组(P<0.05);观察组EORTCQLQ-C30中健康状况与功能领域评分均高于对照组,症状维度评分低于对照组(P<0.05);观察组不良反应总发生率低于对照组(P<0.05)。结论:贝伐珠单抗靶向治疗联合TC化疗方案能提高晚期非小细胞肺癌患者临床疗效,降低血清VEGF、CEA、CYFRA21-1水平的同时提高患者生活质量,且不良反应低。
Objective:To observe the efficacy of bevacizumab targeted therapy combined with TC chemotherapy in the treatment of advanced non-small cell lung cancer.Methods:A total of 50 patients with advanced non-small cell lung cancer admitted to our hospital from January 2017 to December 2020 were randomly divided into control group and observation group,with 25 cases in each group.The control group was treated with standard TC chemotherapy,and the observation group was treated with bevacizumab targeted therapy combined with TC chemotherapy.The clinical efficacy,serum vascular endothelial growth factor(VEGF),serum carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1)level,quality of life of cancer patients(EORTC-QLQ-C30)score and adverse reactions were observed and compared between the two groups.Results:The clinical remission rate and disease control rate of the observation group were higher than those of the control group(P<0.05).The levels of serum VEGF,CEA and CYFRA21-1 in the observation group were lower than those in the control group(P<0.05).The scores of health status and functional areas in EORTC-QLQ-C30 in the observation group were higher than those in the control group,and the symptom dimension score was lower than that in the control group(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion:Bevacizumab targeted therapy combined with TC chemotherapy can improve the clinical efficacy of patients with advanced non-small cell lung cancer,reduce serum VEGF,CEA,and CYFRA21-1 levels while improving the quality of life of patients with low adverse reactions.
作者
曾红梅
李欣
ZENG Hongmei;LI Xin(Department of Oncology,People’s Hospital of Zigui County,Zigui 443600,Hubei,China;Department of Radiotherapy,Second People’s Hospital of Yichang,Yichang 443000,Hubei,China)
出处
《中国药物滥用防治杂志》
CAS
2022年第3期308-312,共5页
Chinese Journal of Drug Abuse Prevention and Treatment
关键词
晚期非小细胞肺癌
贝伐珠单抗
TC化疗方案
生存质量
Advanced non-small cell lung cancer
Bevacizumab
TC chemotherapy regimen
Quality of life
作者简介
曾红梅(1969.02—),女,汉族,湖北秭归人,本科,副主任医师,主要研究方向:肿瘤内科诊疗。邮箱:wfyssci@163.com;通信作者:李欣(1968.01—),男,汉族,湖北宜昌人,本科,主任医师,主要研究方向:肿瘤学放射治疗。邮箱:sprma29@163.com。
